Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
Dr. Peter Bach, a physician and epidemiologist, directs the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center in New York. An oft-quoted source and contributor to various mainstream media, one of his seminal writings was a 2012 New York Times op-ed explaining, alongside his hospital colleagues, Memorial’s decision not to prescribe the then-new colorectal cancer drug Zaltrap. The drug was equally effective as the standard of care but cost twice as much, meaning it offered half the value. Drugmaker Sanofi subsequently caved on price.
That kind of directness has made Bach quite influential amid ongoing efforts to rein in healthcare costs and improve quality.
He’s not only a frequent critic of drug pricing but also an exponent of the concept of “value” in medicine. That’s a term of which pharmaceutical marketers aren’t too fond of, but their hospitals/integrated delivery networks and payer customers certainly are.